Ventilation system testing services

IOM carry out the validation and annual verification of specialised ventilation systems. A principal requirement of HTM 03-01 and HTM 2025 that relates to the design and air rate testing of hospital ventilation systems for critical areas including:

  • Operating Theatre Suites
  • Conventional operating theatres
  • Ultra-clean operating theatres
  • Day theatres
  • Minor procedures rooms
  • Healthcare clinics
  • Recovery areas
  • Hospital wards
  • Sterile Service Departments including IAP rooms
  • Aseptic suites
  • Isolation rooms
  • Mortuaries
  • Pharmacies
  • IVF treatment suites
  • ITU departments
  • HDU departments
  • Category 2 and 3 laboratories

Providing UK coverage from our Stafford office, we offer extensive knowledge and expertise in the verification and validation of specialised ventilation for healthcare premises and will ensure the necessary work is carried out to fit in with your tight theatre schedules.

New and old healthcare ventilation systems vary in complexity and any design or performance shortcomings can have potentially serious consequences in the battle to control airborne infection. Under-resourced and overworked hospital engineers, theatre managers and infection control departments can rely upon our assistance to comply with HTM 03-01 and HTM 2025 in critical decision making that affects patient care in operating theatres and general healthcare environments.

Events
20 October
2021
In partnership with the ICBA

Particles and Health 2021

  • 20 October 2021
  • Running from the 20.10.21 to 21.10.21

IOM is proud to be sponsoring the Particles and Health conference, a two day event designed for regulators and researchers to:

  • Address scientific studies regarding human health effects of PSLTs. The value of human studies over animal studies-when human-exposed populations can be studied adequately- will be emphasized.
  • Review and discuss definition of PSLT’s proposed at Edinburgh workshop and published in 2020 in the Journal Inhalation Toxicology with attention to both similarities and differences among these substances.
  • Address translational toxicology challenges, including the appropriateness of rats as models for human lung pathogenesis (particularly lung cancer) in light of lung overload phenomena and species differences.
  • Serve as a platform to present current scientific information about PSLTs important for regulatory action.
  • Publication of pertinent conference presentations in the peer reviewed scientific literature will allow the presentations to live beyond the conference and subsequently be reviewed part of regulatory deliberations.
  • Establish an interdisciplinary setting for industry, academia and regulatory professionals to interact on an important topic. Such interaction can facilitate enhanced understanding of the science and appropriate classification, labelling and setting exposure limits, among others.
  • Recommend areas for further research regarding the significance of the rat as a model for translation toxicology. 
  • Review the biokinetics of inhaled nanoparticles and the potential for non-pulmonary effects.

For more information and tickets please visit the Particles and Health website here.

Event info
We're here to provide you with more information and answer any questions you may have. Contact us